TipRanks
Go Ultimate55% OFF

Compare Knight Therapeutics (04K) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:04KKnight TherapeuticsEUR 7.25EUR 706.97M76.61104.80%Strong BuyUnlock the DE:04K analyst price target with TipRanks PremiumDE:04KUnlock the DE:04K top-analyst price target with TipRanks Premium
TSE:CPHCipher PharmaceuticalsCAD 13.05CAD 331.67M8.19-8.87%Moderate BuyUnlock the TSE:CPH analyst price target with TipRanks PremiumDE:04K vs TSE:CPHUnlock the TSE:CPH top-analyst price target with TipRanks Premium
TSE:OGIOrganigram GlobalCAD 1.32CAD 186.13M2.05-40.54%Moderate BuyUnlock the TSE:OGI analyst price target with TipRanks PremiumDE:04K vs TSE:OGIUnlock the TSE:OGI top-analyst price target with TipRanks Premium
TSE:ACBAurora CannabisCAD 5.66CAD 372.12M-2.93-16.02%Moderate BuyUnlock the TSE:ACB analyst price target with TipRanks PremiumDE:04K vs TSE:ACBUnlock the TSE:ACB top-analyst price target with TipRanks Premium
TSE:CRONCronos GroupCAD 4.62CAD 1.70B17.6135.48%Moderate BuyUnlock the TSE:CRON analyst price target with TipRanks PremiumDE:04K vs TSE:CRONUnlock the TSE:CRON top-analyst price target with TipRanks Premium
TSE:HLSHLS Therapeutics IncCAD 4.51CAD 139.52M-12.23-18.74%Moderate BuyUnlock the TSE:HLS analyst price target with TipRanks PremiumDE:04K vs TSE:HLSUnlock the TSE:HLS top-analyst price target with TipRanks Premium

Performance Comparison

-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:04KKnight Therapeutics7.253.65101.39%
TSE:CPHCipher Pharmaceuticals13.05-1.69-11.47%
TSE:OGIOrganigram Global1.32-0.88-40.00%
TSE:ACBAurora Cannabis5.66-1.20-17.49%
TSE:CRONCronos Group4.621.0629.78%
TSE:HLSHLS Therapeutics Inc4.51-0.99-18.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts